ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call Transcript

SA Transcripts 162.37K Followers Follow ProQR Therapeutics N.V. ( PRQR ) Shareholder/Analyst Call September 30, 2026 11:00 AM EDT Company Participants Sarah Kiely - Vice President of Investor Relations & Corporate Communications Daniel de Boer - Founder, CEO & Executive Director Golnar Karimian Cristina Lopez Lopez - Chief Medical Officer Conference Call Participants Gideon Hirschfield Steven Seedhouse - Cantor Fitzgerald & Co., Research Division Alec Stranahan - BofA Securities, Research Division Konstantinos Biliouris - Oppenheimer & Co. Inc., Research Division Catherine Novack - JonesTrading Institutional Services, LLC, Research Division Sushila Hernandez - Kempen & Co. N.V., Research Division Ryan Deschner - Raymond James & Associates, Inc., Research Division Jonathan Wolleben - Citizens JMP Securities, LLC, Research Division Kaey Nakae - Chardan Capital Markets, LLC, Research Division Ananda Ghosh - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good morning, everyone, and welcome to the ProQR Therapeutics Virtual Investor and Analyst Educational Event. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made available on the ProQR website following the conclusion of the event. I'd now like to turn the call over to Sarah Kiely, Vice President of Investor Relations and Corporate Affairs at ProQR Therapeutics. Please go ahead, Sarah. Sarah Kiely Vice President of Investor Relations & Corporate Communications Thank you all for joining us today. We're pleased to present our educational event, NTCP modulation in biliary atresia via liver-targeted RNA editing. During this presentation, we will make forward-looking statements, and actual results may differ materially from those described. Please refer to our SEC filings for a discussion of risks associated with an investment in ProQR. Let me now briefly walk you through today's agenda. We will start with opening remarks from our Founder and CEO, Daniel de Boer. Next, Dr. Golnar Karimian, our Head of Hepatology, will discuss the rationale for NTCP modulation in biliary atresia and our recent target engagement clinical data with AX-0810. We are